Evergreen Capital Management boosted its Regeneron stake by 362.9%, snatching up 3,030 more shares and flexing some serious ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Leerink Partnrs analyst M. Cherny now expects that the medical research company will earn $2.58 per share for the quarter, down from their prior estimate of $2.59. Leerink Partnrs currently has a ...

That “may be the largest increase we have seen,” Whit Mayo, an analyst with Leerink Partners, wrote in a Monday note. “This reads very positive” for insurers, Mayo said. It’s not ...

On the bright side, Leerink Partners upgraded Regeneron to a “strong-buy,” proving at least one analyst still believes in scientific miracles and stock rebounds. Despite the lukewarm analyst sentiment ...

Leerink Partnrs also issued estimates for NeuroPace’s Q2 2025 earnings at ($0.24) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.20) EPS, FY2026 earnings at ($0.51) EPS, FY2027 ...

Regeneron Pharmaceuticals saw its share price decline by 10% over the past week. The recent approval of Dupixent for COPD in Japan was expected to bolster investor confidence, yet the broader ...

Regeneron Pharmaceuticals Inc REGN raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often ...

Biotech stocks toppled early Thursday after Trump announced broad global tariffs, including a 20% tariff on goods from Europe.

It was previously corrected to change the brokerage's name to Leerink Partners, not Jefferies, in paragraph 4) Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's ...